Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis

Real-world evidence from Germany and the US shows that initiating MS treatment with high-efficacy therapies reduces the need for switching treatments—unlocking more stable, effective long-term disease management and transforming patient outcomes.

By Steffeni Papukchieva, Hyung-Do Kim, Ann-Sophie Stratil , Emily Magurne , Apolline Jonckheere , Maria Kahn , Sebastian Schneeweiss , Tjalf Ziemssen , Benjamin Friedrich;  Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis;Multiple Sclerosis and Related Disorders. Volume 88, August 2024, 105751